Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
Alloy Therapeutics and Pyxis Oncology launched Voxall Therapeutics, a joint venture focused on developing novel immune-modulating antibody therapies for cancer and autoimmune diseases. The collaboration integrates Alloy’s ATX-Gx™ discovery platform with Pyxis’ target expertise and preclinical capabilities, facilitated by Alloy’s 82VS venture studio. LEXINGTON & CAMBRIDGE, Mass., May 25th, 2021 – Alloy Therapeutics (“Alloy”) and […]
Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem
Funds to be used to advance platforms and resources used by scientific entrepreneurs to turn ideas into biological medicines.
Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases
Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases.